The UK's largest pharmaceutical company, Rafa, has announced a joint partnership with the British Pharmaceuticals and Drug Administration (FDA) to promote access to medicines for rare diseases in developing countries in the Middle East and Eastern Europe (CEE).
Source: prnewswire.comPublished on 2022-08-02
Related news
- The Worldwide Beacon Industry is Expected to Reach $14
- Presentation to the National Space Council User Advisory Group by Thomas Zurbuchen
- WISeKey WISe . ART NFT Marketplace adds new collection of NFTs from new artists
- Artificial intelligence deep learning model for mapping wetlands yields 94 % accuracy
- Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
- Covid in Scotland : One further death as vaccine stats hit with technical issues
- Coronavirus Update : First made - in - Canada coronavirus vaccine gets tentative greenlight
- How To Make Individual Healthcare Data Ownership A Reality
- Intesa Sanpaolo launches new startup development programme
- SKT to Lead AI Transformation in Industry and Society with AI Services and Technologies
- Open Mineral and Sherritt partner to tackle arsenic in precious metal concentrates
- Why has Da Nang taken the lead in digital transformation ?
- Cairngorms National Park gets the Minecraft treatment
- The fifth techUK Digital Ethics Summit : Reflecting on the past and the future
- NICE Alliance Welcomes Total Building Solution Provider S & I Corp . as Adopter for Global Expansion of Advanced AI - Based Facility Management ( FM ) Service